'Leukemia group' presentation slideshows

OBVIOUS DIFFERENCES

OBVIOUS DIFFERENCES. Other medical conditions in adults - effects of [subclinical] organ dysfunction on drug disposition Better tolerance in children with ability to deliver repetitive courses more easily (eg. l-aspariginase) Need for more of a focus on long term toxicities in children.

259 views • 18 slides

Reprinted with permission from the American Society of Clinical Oncology.

Figure 1 CALGB (Cancer and Leukemia Group B) 9221: Median time to transformation to acute myeloid leukemia or death in patients with myelodysplastic syndrome treated with azacitidine or given best supportive care. Reprinted with permission from the American Society of Clinical Oncology.

97 views • 1 slides

Reprinted with permission from the American Society of Clinical Oncology.

129 views • 1 slides